palivizumab biosimilar (Bioceros)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namepalivizumab biosimilar (Bioceros)

Drug Alias NameUndisclosed biosimilar (Bioceros)BC-009

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionRespiratory syncytial virus F protein modulators

TargetsRespiratory syncytial virus F protein

Therapy Area/IndicationsRespiratory Syncytial Virus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBioceros

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBioceros

Active IndicationsN/A

Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A